Vedolizumab for treating moderate to severe active ulcerative colitis or Crohn’s disease in paediatrics

Vedolizumab is being developed as a treatment for moderate to severe ulcerative colitis and Crohn’s disease. These conditions are chronic (long-term) and cause inflammation in the digestive system. Both conditions are types of inflammatory bowel disease, which affects the gut and can significantly impact daily life. Current treatment options can cause harmful side effects and may stop working overtime. Therefore, there is a need for new treatments that can directly control inflammation in the gut with less risk of side effects.